These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 6343431)

  • 1. Heart disease: the MRFIT test.
    Szklo M
    J Public Health Policy; 1983 Mar; 4(1):5-7. PubMed ID: 6343431
    [No Abstract]   [Full Text] [Related]  

  • 2. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial.
    Grimm RH; Svendsen KH; Kasiske B; Keane WF; Wahi MM
    Kidney Int Suppl; 1997 Dec; 63():S10-4. PubMed ID: 9407412
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular diseases: a review of the Hispanic perspective. Awareness is the first step to action.
    López-Candales A
    J Med; 2002; 33(1-4):227-45. PubMed ID: 12939121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Additive benefits of pravastatin and aspirin to decrease risks of cardiovascular disease: randomized and observational comparisons of secondary prevention trials and their meta-analyses.
    Hennekens CH; Sacks FM; Tonkin A; Jukema JW; Byington RP; Pitt B; Berry DA; Berry SM; Ford NF; Walker AJ; Natarajan K; Sheng-Lin C; Fiedorek FT; Belder R
    Arch Intern Med; 2004 Jan; 164(1):40-4. PubMed ID: 14718320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The HOPE study: comparison with other trials of secondary prevention.
    Otterstad JE; Sleight P
    Eur Heart J; 2001 Aug; 22(15):1307-10. PubMed ID: 11465962
    [No Abstract]   [Full Text] [Related]  

  • 6. [The MRFIT, HDFP and Oslo studies: the important data. Multiple Risk Factor Intervention Trial. Hypertension Detection and Follow-up Program].
    Svärdsudd K
    Cardiologia; 1984; 29(1-2):53-62. PubMed ID: 6398706
    [No Abstract]   [Full Text] [Related]  

  • 7. Tissue ACE inhibitors for secondary prevention of cardiovascular disease in patients with preserved left ventricular function: a pooled meta-analysis of randomized placebo-controlled trials.
    Saha SA; Molnar J; Arora RR
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):192-204. PubMed ID: 17875946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is there a role for antioxidant vitamins in the prevention of cardiovascular diseases? An update on epidemiological and clinical trials data.
    Lonn EM; Yusuf S
    Can J Cardiol; 1997 Oct; 13(10):957-65. PubMed ID: 9374952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Mortality from cardiovascular diseases in patients with type 2 diabetes].
    Janeczko D; Kopczyński J; Lewandowski Z; Janeczko-Sosnowska E; Tuszyńska A
    Przegl Lek; 2000; 57 Suppl 4():3-7. PubMed ID: 11293227
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular disease and intensive glucose lowering in type 2 diabetes.
    Younis N; Soran H; Hassanein M
    QJM; 2009 Apr; 102(4):293-6. PubMed ID: 19147659
    [No Abstract]   [Full Text] [Related]  

  • 11. Mortality in 4100 insured applicants with ECG and chest X-ray: relation to cardiovascular and other risk factors, including relative heart diameter.
    Singer RB; Siber FJ; Brown AE; Pitkin FI
    Trans Assoc Life Insur Med Dir Am; 1982; 65():180-93. PubMed ID: 7135711
    [No Abstract]   [Full Text] [Related]  

  • 12. [Health and cardiovascular diseases in women].
    Beiras AC
    Rev Esp Cardiol; 1994; 47 Suppl 3():1-5. PubMed ID: 7816973
    [No Abstract]   [Full Text] [Related]  

  • 13. Exercise workload, coronary risk evaluation and the risk of cardiovascular and all-cause death in middle-aged men.
    Laukkanen JA; Rauramaa R; Kurl S
    Eur J Cardiovasc Prev Rehabil; 2008 Jun; 15(3):285-92. PubMed ID: 18525382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cardiovascular comorbidity in rheumatic disease. Does sex play a role?].
    Kung M; Störk S; Angermann CE
    Herz; 2005 Sep; 30(6):512-21. PubMed ID: 16170682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term cardiovascular mortality among middle-aged men with gout.
    Krishnan E; Svendsen K; Neaton JD; Grandits G; Kuller LH;
    Arch Intern Med; 2008 May; 168(10):1104-10. PubMed ID: 18504339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What is my risk of developing cardiovascular disease?
    Graham IM; Cooney MT; Dudina A; Squarta S
    Eur J Cardiovasc Prev Rehabil; 2009 Aug; 16 Suppl 2():S2-7. PubMed ID: 19675432
    [No Abstract]   [Full Text] [Related]  

  • 17. The association of resting heart rate with cardiovascular, cancer and all-cause mortality. Eight year follow-up of 3527 male Israeli employees (the CORDIS Study).
    Kristal-Boneh E; Silber H; Harari G; Froom P
    Eur Heart J; 2000 Jan; 21(2):116-24. PubMed ID: 10637085
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of postmenopausal hormone therapy on cardiovascular events and cancer. More women are excluded from treatment arm of such trials because of cardiovascular events.
    Singleton S; Bailey K
    BMJ; 1997 Sep; 315(7109):676. PubMed ID: 9310575
    [No Abstract]   [Full Text] [Related]  

  • 19. Improved hypertension control and decline in cardiovascular mortality.
    Soltero I; Cooper R
    Compr Ther; 1980 Mar; 6(3):60-4. PubMed ID: 7363585
    [No Abstract]   [Full Text] [Related]  

  • 20. Olive oil, the mediterranean diet, and cardiovascular health.
    Huang CL; Sumpio BE
    J Am Coll Surg; 2008 Sep; 207(3):407-16. PubMed ID: 18722947
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.